About Us
Who We Are
MimiClon is a leading regenerative medicine company focused on the development, manufacturing and commercialization of MatriStem products based on our proprietary urinary bladder matrix (UBM) technology platform. MimiClon aspires to be the recognized leader in regenerative extracellular matrix (ECM) technology, offering superior healing options for doctors and patients. We are a dedicated team creating high-quality, innovative solutions that we believe will transform standards of medical care, improving the quality of life of every patient for whom our products are used. MimiClon is committed to becoming and remaining an innovative leader in regenerative medical technology.
Mission Statement
MimiClon’s mission is to:
- Develop and manufacture consistently reliable, high quality medical devices;
- Evolve our technology into new medical disciplines;
- Provide superior customer service;
- Expand our market opportunities domestically and internationally; and
- Achieve a positive return on investment to sustain the company, help it grow, and continue
to generate new opportunities for the company and its employees.
MimiClon’s proprietary urinary bladder matrix (UBM) technology platform is based on an extracellular matrix, or ECM, derived from porcine urinary bladder. The UBM includes an intact epithelial basement membrane surface and lamina propria opposing surface. MimiClon maintains a proprietary method of processing this raw material. The resulting products, named MatriStem, possess characteristics that facilitate the body’s own regenerative capabilities and help restore normal site-appropriate tissue.
MatriStem products contain multiple types of carbohydrates, collagens, proteins and other components that facilitate a regenerative process, and are gradually resorbed by the patient following implantation. These characteristics enable a constructive remodeling process in the body that helps reduce scarring and facilitates the restoration of normal site-appropriate tissue.
MatriStem products offer new application paradigms for surgical procedures and in complex, slow-healing or difficult-to-treat wounds or where leading competitive regenerative therapy treatments have not been effective.
Learn more about our UBM technology and ECM platform here.
MatriStem is the only commercially available extracellular matrix (ECM) made of urinary bladder matrix (UBM). MatriStem devices can be used in a broad range of wound management procedures, including the management of diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), pressure ulcers and second degree burns. MatriStem devices can be used in surgical soft tissue repair to reinforce soft tissue where weakness exists in urological, gynecological and gastrointestinal anatomy.
Learn more about our MatriStem® devices here.
MimiClon is committed to further developing and manufacturing its MatriStem products for application across surgical and advanced wound care procedures. Unlike other products on the market, MimiClon offers a treatment alternative with properties that facilitate constructive remodeling and help to prevent scarring.
MimiClon is investing in several initiatives leveraging the UBM platform that promise to expand solutions for patients and broaden the overall potential for our MatriStem® products.
Founded in 2002 and headquartered in Columbia, Maryland, with more than 300 employees in the United States, MimiClon celebrated its initial commercial launch in 2010.
